Daré Bioscience Statistics
Share Statistics
Daré Bioscience has 8.85M
shares outstanding. The number of shares has increased by -91.39%
in one year.
| Shares Outstanding | 8.85M |
| Shares Change (YoY) | -91.39% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.11% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 140 |
| FTD / Avg. Volume | 0.78% |
Short Selling Information
The latest short interest is 60.81K, so 0.69% of the outstanding
shares have been sold short.
| Short Interest | 60.81K |
| Short % of Shares Out | 0.69% |
| Short % of Float | 0.7% |
| Short Ratio (days to cover) | 5.58 |
Valuation Ratios
The PE ratio is -6.54 and the forward
PE ratio is -3.02.
Daré Bioscience's PEG ratio is
0.07.
| PE Ratio | -6.54 |
| Forward PE | -3.02 |
| PS Ratio | 2709.74 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 5.5 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Daré Bioscience.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.85,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.85 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.37 |
| Debt / FCF | 0.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $465.9 |
| Profits Per Employee | $-193,028.52 |
| Employee Count | 21 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.05B |
| Effective Tax Rate | 99.9% |
Stock Price Statistics
The stock price has increased by -41.26% in the
last 52 weeks. The beta is 1.2, so Daré Bioscience's
price volatility has been higher than the market average.
| Beta | 1.2 |
| 52-Week Price Change | -41.26% |
| 50-Day Moving Average | 2.91 |
| 200-Day Moving Average | 3.24 |
| Relative Strength Index (RSI) | 56.96 |
| Average Volume (20 Days) | 18,035 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of 9.78K
and earned -4.05M
in profits. Earnings per share was -0.48.
| Revenue | 9.78K |
| Gross Profit | 9.78K |
| Operating Income | -23.45M |
| Net Income | -4.05M |
| EBITDA | -3.54M |
| EBIT | -23.45M |
| Earnings Per Share (EPS) | -0.48 |
Full Income StatementBalance Sheet
The company has 15.7M in cash and 1.3M in
debt, giving a net cash position of 14.4M.
| Cash & Cash Equivalents | 15.7M |
| Total Debt | 1.3M |
| Net Cash | 14.4M |
| Retained Earnings | -175.29B |
| Total Assets | 18.62M |
| Working Capital | -9.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 5.39M
and capital expenditures -573.05K, giving a free cash flow of 4.82M.
| Operating Cash Flow | 5.39M |
| Capital Expenditures | -573.05K |
| Free Cash Flow | 4.82M |
| FCF Per Share | 0.57 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -239692.2% and -41430.9%.
| Gross Margin | 100% |
| Operating Margin | -239692.2% |
| Pretax Margin | -41430897.38% |
| Profit Margin | -41430.9% |
| EBITDA Margin | -36184.25% |
| EBIT Margin | -239692.2% |
| FCF Margin | 49276.38% |
